Multiple Myeloma

NICE Set to Reject Janssen's Darzalex for Multiple Myeloma

(PharmaTimes [UK]) Mar 17, 2017 - Janssen said it is extremely concerned that the National Institute for Health and Care Excellence (NICE) has not recommended Darzalex for treatment of relapsed and refractory multiple myeloma in adults in preliminary guidelines.

read article

FDA Puts Partial Hold On Karyopharm's Cancer Drug

(BioPharma Dive) Mar 12, 2017 - Karyopharm Therapeutics said March 10 it has responded to written notice from the Food and Drug Administration that clinical trials for the pharma’s oncology drug selinexor (KPT-330) have been placed on partial clinical hold.

read article

Mayo Clinic Researchers Identify Therapy That Shrinks Tumors In Patients With Multiple Myeloma

(Mayo Clinic) Mar 8, 2017 - Mayo Clinic researchers have found that an experimental drug, LCL161, stimulates the immune system, leading to tumor shrinkage in patients affected by multiple myeloma.

read article

CNN Profiles Black Swan Research Initiative’s Innovative iStopMM Project And Asks “Why Iceland?”

(International Myeloma Foundation) Mar 1, 2017 - The iStopMM testing in Iceland of 4,000 patients with monoclonal gammopathy of undetermined significance (MGUS), a precursor state to myeloma, will allow researchers to look for linkages to particular family gene patterns.

read article

Amgen Presents Overall Survival Data From KYPROLIS (carfilzomib) Phase 3 ENDEAVOR Trial At 16th International Myeloma Workshop

(Amgen) Mar 3, 2017 - Late-breaking presentation to show overall survival benefit of KYPROLIS compared to Velcade® (bortezomib) in relapsed or refractory multiple myeloma patients; first-and-only head-to-head study comparing proteasome inhibitors to demonstrate statistically significant improved overall survival.

read article

Amgen Presents New Data From Phase 3 XGEVA® (denosumab) Study In Multiple Myeloma Patients At The 16th International Myeloma Workshop

(Amgen) Mar 3, 2017 - Results to be presented as late-breaking oral presentation; largest international trial conducted in multiple myeloma; study met primary endpoint of non-inferiority versus zoledronic acid in delaying bone complications known as skeletal-related events.

read corporate press release

Amgen To Present New KYPROLIS® (Carfilzomib) And XGEVA® (Denosumab) Data At The 16th International Myeloma Workshop

(The Business Journals) Mar 1, 2017 - Detailed results from phase 3 head-to-head Endeavor trial show Kyprolis significantly improved overall survival compared to Velcade® (bortezomib) in relapsed or refractory multiple myeloma patients; late-breaking results from largest international trial conducted in multiple myeloma show Xgeva was non-inferior versus zoledronic acid in delaying bone complications.

read article

Longer Survival Seen With Amgen's Kyprolis vs Velcade In Myeloma Study

(Reuters) Feb 28, 2017 - Patients with relapsed multiple myeloma treated with Amgen Inc's Kyprolis lived more than seven months longer than those who received Takeda Pharmaceutical Co's Velcade, according to data from a late-stage study released by Amgen on Tuesday.

read article

First Opinion: The Power — And The Fear — Of Knowing Your Cancer Genome

(STAT Plus) Feb 23, 2017 - When it comes to cancer, all knowledge is power — even when that knowledge is scary. Knowing as much as you can about cancer lets you and your health care team act decisively in devising your treatment strategy.

read article (paid subscription required)

CHMP Issues Positive Opinion Recommending DARZALEX® (daratumumab) for Relapsed or Refractory Multiple Myeloma

(Morningstar) Feb 24, 2017 - CHMP issued positive opinion for DARZALEX for relapsed or refractory multiple myeloma; final decision from European Commission expected in the coming months; opinion based on data from two Phase III studies, CASTOR and POLLUX.

read article

REVLIMID® (Lenalidomide) Approved by the European Commission as Monotherapy for the Maintenance Treatment of Patients with Newly Diagnosed Multiple Myeloma After Autologous Stem Cell Transplantation

(Celgene) Feb 24, 2017 - Oral REVLIMID® is the first and only medicine licensed in Europe for use as post-autologous stem cell transplantation maintenance therapy in multiple myeloma; the new indication expands the availability of REVLIMID® across the disease continuum of multiple myeloma.

read corporate press release

FDA Expands Indication for REVLIMID® (lenalidomide) as a Maintenance Treatment for Patients with Multiple Myeloma Following Autologous Hematopoietic Stem Cell Transplant (auto-HSCT)

(Celgene) Feb 22, 2017 - REVLIMID is the first and only treatment approved for maintenance following auto-HSCT; updated data from two large, randomized, controlled studies demonstrated median progression-free survival (PFS) advantages of 3.8 and 1.9 years, respectively, in favor of patients receiving REVLIMID compared to no maintenance.

read corporate press release

FDA Approves Lenalidomide as Maintenance Therapy for Patients with Multiple Myeloma Following Autologous Stem Cell Transplant

(ASCO in Action) Feb 22, 2017 - On February 22, 2017, the U.S. Food and Drug Administration approved lenalidomide (Revlimid®, Celgene Corp.) as maintenance therapy for patients with multiple myeloma following autologous stem cell transplant.

read article

Genmab and J&J's Cancer Drug Set for Blockbuster Sales This Year

(Reuters) Feb 22, 2017 - Danish biotech drugmaker Genmab expects sales of Darzalex, used to fight cancer in bone marrow, to surpass $1 billion (0.80 billion pounds) this year to become a blockbuster drug, the company said on Wednesday.

read article

Three-Drug Combination Extends Survival for Patients with Multiple Myeloma

(NCI/Cancer Currents Blog) Feb 10, 2017 - A phase III clinical trial demonstrates that adding the drug bortezomib to a commonly used two-drug regimen extends survival in patients with newly diagnosed multiple myeloma.

read article

HIV Drug Active in Refractory Myeloma

(MedPage Today) Dec 8, 2016 - Two-thirds of patients with proteasome inhibitor-refractory myeloma responded to the antiretroviral agent nelfinavir, added to standard myeloma agents, according to a small study reported here.

read article (free registration required)

How is European Immuno-Oncology Fighting Blood Cancer?

( Dec 6, 2016 - From leukemia to multiple myeloma, biotech is working hard to cure blood cancer. This year’s edition of the American Society of Hematology (ASH) annual meeting features immuno-oncology therapies developed by the best European biotechs, with Novartis taking the lead in the CAR-T field.

read article

Psychosocial Factors Associated With High Readmission Rates Longer Hospital Stays

(OSUCCC - The James) Dec 5, 2016 - A new study shows that psychosocial risk factors that impact a person’s ability to cope with chronic stress are associated with significantly higher readmission rates and longer hospital stays among blood cancer patients undergoing hematopoietic stem cell transplantation (HSCT).

read press release

Phase III Studies Present Additional Evidence for REVLIMID® (lenalidomide) as Maintenance Therapy in Multiple Myeloma

(Celgene) Dec 6, 2016 - Celgene Corporation, today announced results from two studies (Abstracts #1143, LBA-1) evaluating the investigational use of REVLIMID® (lenalidomide) maintenance therapy in patients with multiple myeloma.

read corporate press release

Additions to Standard Multiple Myeloma Therapy Do Not Appear to Yield Additional Benefit

(ASH) Dec 6, 2016 - Largest randomized trial finds second round of chemotherapy or stem cell transplant does not improve progression-free survival.

read press release
Next Page